Gilead Sciences Inc (GILD)

Jan 15, 2025, 3:45 PM EST - 2 days ago

Gilead Sciences, US government settle patent case over HIV prevention drugs

Jan 13, 2025, 6:32 PM EST - 4 days ago

Final Trade: ANF, GILD

ANF

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GSK IBB

Jan 13, 2025, 5:09 PM EST - 4 days ago

Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

Jan 13, 2025, 11:15 AM EST - 4 days ago

Gilead CEO on funding for new HIV prevention medicine

Jan 13, 2025, 11:11 AM EST - 4 days ago

Gilead's new HIV prevention drug lenacapavir will ‘change the face of HIV,' says CEO Daniel O'Day

Jan 13, 2025, 9:01 AM EST - 4 days ago

Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV

Jan 11, 2025, 12:40 PM EST - 6 days ago

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Jan 11, 2025, 11:00 AM EST - 6 days ago

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Dec 29, 2024, 3:51 AM EST - 19 days ago

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

Dec 20, 2024, 4:05 PM EST - 4 weeks ago

Gilead Sciences to Present at Upcoming Investor Conference

Dec 18, 2024, 1:53 AM EST - 4 weeks ago

Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure

Dec 17, 2024, 8:30 AM EST - 4 weeks ago

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Dec 17, 2024, 7:00 AM EST - 4 weeks ago

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

Dec 13, 2024, 6:37 AM EST - 5 weeks ago

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Dec 12, 2024, 5:54 PM EST - 5 weeks ago

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

SNY

Dec 12, 2024, 5:30 PM EST - 5 weeks ago

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Dec 10, 2024, 6:50 PM EST - 5 weeks ago

Final Trade: LMAT, GOOGL, IBM, GILD

GOOG GOOGL IBM LMAT

Dec 9, 2024, 5:45 PM EST - 5 weeks ago

Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Dec 9, 2024, 4:30 PM EST - 5 weeks ago

Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Dec 8, 2024, 12:30 PM EST - 5 weeks ago

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Dec 4, 2024, 2:39 PM EST - 6 weeks ago

Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Dec 3, 2024, 1:47 PM EST - 6 weeks ago

Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)

Dec 3, 2024, 7:00 AM EST - 6 weeks ago

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

Nov 27, 2024, 5:00 PM EST - 7 weeks ago

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Nov 26, 2024, 1:28 PM EST - 7 weeks ago

The Best Large-Cap Stocks to Buy

ABT AMGN BSX CRM GS INTU MDT

Nov 22, 2024, 4:24 PM EST - 2 months ago

The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.

Nov 20, 2024, 11:45 AM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)

Nov 15, 2024, 2:14 PM EST - 2 months ago

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Nov 15, 2024, 11:00 AM EST - 2 months ago

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Nov 14, 2024, 12:52 AM EST - 2 months ago

Gilead Sciences to close Seattle office; shutdown impacts 72 employees

Nov 13, 2024, 8:24 PM EST - 2 months ago

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Nov 13, 2024, 6:45 AM EST - 2 months ago

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Nov 12, 2024, 5:30 AM EST - 2 months ago

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

Nov 8, 2024, 4:44 PM EST - 2 months ago

Gilead Sciences: Finally Some Real Momentum

Nov 8, 2024, 4:05 PM EST - 2 months ago

Gilead Sciences to Present at Upcoming Investor Engagements

Nov 7, 2024, 1:46 PM EST - 2 months ago

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

Nov 7, 2024, 8:40 AM EST - 2 months ago

Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year

Nov 7, 2024, 8:30 AM EST - 2 months ago

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

Nov 6, 2024, 8:58 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:36 PM EST - 2 months ago

Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance

Nov 6, 2024, 4:20 PM EST - 2 months ago

Gilead 3rd-quarter results beat Wall Street estimates, raises outlook

Nov 6, 2024, 4:02 PM EST - 2 months ago

Gilead Sciences Announces Third Quarter 2024 Financial Results

Nov 5, 2024, 9:15 AM EST - 2 months ago

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

Nov 4, 2024, 12:28 PM EST - 2 months ago

Top 2 pharma stocks to buy amid surge in deadly fungi

MRK

Oct 22, 2024, 9:00 AM EDT - 3 months ago

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Oct 21, 2024, 1:34 PM EDT - 3 months ago

Calls of the Day: Gilead, Berkshire Hathaway and SLB

SLB

Oct 21, 2024, 8:27 AM EDT - 3 months ago

This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

JD GTLB MHK WRBY

Oct 19, 2024, 5:09 PM EDT - 3 months ago

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

MRK

Oct 18, 2024, 8:50 AM EDT - 3 months ago

Gilead voluntarily withdraws urothelial cancer drug in US